Trial Profile
An Open-label, Single-dose Phase 1 Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 in Healthy Korean and Caucasian Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Lazertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Yuhan
- 01 Jan 2023 Results assessing Effects of food and race on the pharmacokinetics of lazertinib (from 3 studies NCT03556436: Healthy subjects N = 24; NCT03046992 n=30 Asian subjects and NCT04075396, n=22 non Asian patients NSCLC patients ) in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer published in the Lung Cancer
- 14 Jan 2019 Status changed from recruiting to completed.
- 06 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.